Stay updated on TKI + Anti-PD-1 in MSS/pMMR mCRC Clinical Trial
Sign up to get notified when there's something new on the TKI + Anti-PD-1 in MSS/pMMR mCRC Clinical Trial page.

Latest updates to the TKI + Anti-PD-1 in MSS/pMMR mCRC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe web page has undergone significant updates, including the addition of a new study on the efficacy and safety of Tyrosine Kinase Inhibitors in combination with anti-PD-1 antibodies for treating MSS/pMMR metastatic colorectal adenocarcinoma, along with a revision update to v2.15.0. Notably, the previous detailed description of the study's purpose and methodology has been removed.SummaryDifference42%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check66 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check87 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
Stay in the know with updates to TKI + Anti-PD-1 in MSS/pMMR mCRC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the TKI + Anti-PD-1 in MSS/pMMR mCRC Clinical Trial page.